INBS Stock Overview
A medical technology company, developing rapid, non-invasive testing, and screening solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Intelligent Bio Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$11.70 |
| 52 Week Low | US$1.00 |
| Beta | 4.72 |
| 11 Month Change | -0.64% |
| 3 Month Change | 29.17% |
| 1 Year Change | -55.46% |
| 33 Year Change | -99.66% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| INBS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.7% | 1.5% | 2.2% |
| 1Y | -55.5% | 20.8% | 31.6% |
Return vs Industry: INBS underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: INBS underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| INBS volatility | |
|---|---|
| INBS Average Weekly Movement | 16.7% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INBS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INBS's weekly volatility has decreased from 34% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 50 | Harry Simeonidis | ibs.inc |
Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse. It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
Intelligent Bio Solutions Inc. Fundamentals Summary
| INBS fundamental statistics | |
|---|---|
| Market cap | US$6.80m |
| Earnings (TTM) | -US$10.42m |
| Revenue (TTM) | US$3.19m |
2.1x
P/S Ratio-0.7x
P/E RatioIs INBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBS income statement (TTM) | |
|---|---|
| Revenue | US$3.19m |
| Cost of Revenue | US$1.65m |
| Gross Profit | US$1.54m |
| Other Expenses | US$11.96m |
| Earnings | -US$10.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 48.31% |
| Net Profit Margin | -326.77% |
| Debt/Equity Ratio | 8.4% |
How did INBS perform over the long term?
See historical performance and comparison